U.S. patent application number 15/375289 was filed with the patent office on 2017-06-01 for methods of growing tumor infiltrating lymphocytes in gas-permeable containers.
This patent application is currently assigned to The USA, as represented by the Secretary, Department of Health and Human Service. The applicant listed for this patent is The USA, as represented by the Secretary, Department of Health & Human Services, The USA, as represented by the Secretary, Department of Health & Human Services, Wilson Wolf Manufacturing Corporation. Invention is credited to Mark E. Dudley, Jianjian Jin, Steven A. Rosenberg, Marianna Sabatino, Robert Somerville, David Stroncek, John R. Wilson.
Application Number | 20170152478 15/375289 |
Document ID | / |
Family ID | 45937598 |
Filed Date | 2017-06-01 |
United States Patent
Application |
20170152478 |
Kind Code |
A1 |
Rosenberg; Steven A. ; et
al. |
June 1, 2017 |
METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE
CONTAINERS
Abstract
An embodiment of the invention provides a method of promoting
regression of cancer in a mammal comprising obtaining a tumor
tissue sample from the mammal; culturing the tumor tissue sample in
a first gas permeable container containing cell medium therein;
obtaining tumor infiltrating lymphocytes (TIL) from the tumor
tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells;
and administering the expanded number of TIL to the mammal. Methods
of obtaining an expanded number of TIL from a mammal for adoptive
cell immunotherapy are also provided.
Inventors: |
Rosenberg; Steven A.;
(Potomac, MD) ; Dudley; Mark E.; (Washington,
DC) ; Stroncek; David; (Rockville, MD) ;
Sabatino; Marianna; (Rockville, MD) ; Jin;
Jianjian; (Clarksburg, MD) ; Somerville; Robert;
(Montgomery Village, MD) ; Wilson; John R.; (New
Brighton, MN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The USA, as represented by the Secretary, Department of Health
& Human Services
Wilson Wolf Manufacturing Corporation |
Bethesda
New Brighton |
MD
MN |
US
US |
|
|
Assignee: |
The USA, as represented by the
Secretary, Department of Health and Human Service
Bethesda
MD
Wilson Wolf Manufacturing Corporation
New Brighton
MN
|
Family ID: |
45937598 |
Appl. No.: |
15/375289 |
Filed: |
December 12, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13424646 |
Mar 20, 2012 |
|
|
|
15375289 |
|
|
|
|
61466200 |
Mar 22, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 2035/124 20130101;
A61K 2039/5158 20130101; A61P 35/00 20180101; C12N 2501/515
20130101; C12N 2502/11 20130101; C12N 2501/2302 20130101; A61K
39/0011 20130101; C12N 5/0634 20130101; C12N 5/0638 20130101; C12N
2501/2315 20130101 |
International
Class: |
C12N 5/078 20060101
C12N005/078; A61K 39/00 20060101 A61K039/00 |
Claims
1. (canceled)
2. A method of obtaining an expanded number of tumor infiltrating
lymphocytes (TIL) from a mammal for adoptive cell immunotherapy
comprising: (a) obtaining a tumor tissue sample from the mammal;
(b) culturing the tumor tissue sample in a first gas permeable
container comprising a cell medium and IL-2; (c) obtaining TIL from
the tumor tissue sample; and (d) expanding the number of TIL in a
second gas permeable container comprising a cell medium, irradiated
feeder cells, IL-2, and OKT3.
3. The method of claim 2, wherein the first permeable container
further comprises IL-15.
4. The method of claim 2, wherein the second permeable container
further comprises IL-15.
5. The method of claim 2, wherein the irradiated feeder cells
comprise allogenic feeder cells.
6. The method of claim 2, wherein the irradiated feeder cells
comprise autologous feeder cells.
7. The method of claim 2, wherein the irradiated feeder cells
comprise irradiated peripheral blood mononuclear cells (PBMCs).
8. The method of claim 2, wherein the step of expanding the number
of TIL comprises expanding the number of TIL over a period of about
10 days to about 14 days.
9. The method of claim 8, wherein the period is about 14 days.
10. The method of claim 2, wherein the method has a duration of
about 28 days to about 42 days.
11. The method of claim 10, wherein the duration is about 28
days.
12. A method for promoting regression of cancer in a mammal
comprising administering the expanded number of TIL of claim 2 to
the mammal.
13. The method of claim 12, wherein the cancer is selected from the
group consisting of acute lymphatic cancer, acute myeloid leukemia,
alveolar rhabdomycosarcoma, bone cancer, brain cancer, breast
cancer, cancer of the anus, anal canal or anorectum cancer, cancer
of the eye, cancer of the intrahepatic bile duct cancer, cancer of
the joints, cancer of the neck, gallbladder or pleura cancer,
cancer of the nose, nasal cavity or middle ear, cancer of the oral
cavity, cancer of the vulva, chronic lymphatic leukemia, chronic
myeloid cancer, colon cancer, esophageal cancer, cervical cancer,
gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma,
hypopharynx cancer, kidney cancer, larynx cancer, liver cancer,
lung cancer, malignant mesothelioma, melanoma, multiple myeloma,
nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer,
pancreatic cancer, peritoneum cancer, omentum and mesentary cancer,
pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin
cancer, small intestine cancer, soft tissue cancer, stomach cancer,
testicular cancer, thyroid cancer, ureter cancer, and urinary
bladder cancer.
14. The method of claim 13, wherein the cancer is melanoma.
15. The method of claim 12, wherein the expanded number of TIL are
administered as an intra-arterial infusion or an intravenous
infusion.
16. The method of claim 12, wherein the expanded number of TIL are
administered through a route of administration selected from the
group consisting of intraperitoneal administration, intrathecal
administration, and intralymphatic administration.
17. The method of claim 12, comprising administering a T-cell
growth factor to the mammal, wherein the T-cell growth factor
comprises one or more of IL-2 and IL-15.
18. The method of claim 17, wherein the T-cell growth factor is
IL-2.
19. The method of claim 17, wherein the T-cell growth factor is
administered to the mammal concomitantly with the expanded number
of TIL.
20. The method of claim 17, wherein the T-cell growth factor is
administered to the mammal subsequently to the expanded number of
TIL.
21. The method of claim 17, wherein the T-cell growth factor is
administered intravenously to the mammal.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This patent application claims the benefit of U.S.
Provisional Patent Application No. 61/466,200, filed Mar. 22, 2011,
which is incorporated by reference in its entirety herein.
BACKGROUND OF THE INVENTION
[0002] Adoptive cell therapy (ACT) using tumor infiltrating
lymphocytes (TIL) can lead to positive, objective, and durable
responses in cancer patients. However, this therapy can involve
sophisticated cell processing techniques and equipment. These
procedures have introduced technical, regulatory, and logistic
challenges to the successful use of TIL as a biological therapy.
Accordingly, there is a need in the art for improved methods for
growing TIL for use in adoptive cell therapy.
BRIEF SUMMARY OF THE INVENTION
[0003] An embodiment of the invention provides a method of
promoting regression of cancer in a mammal comprising obtaining a
tumor tissue sample from the mammal; culturing the tumor tissue
sample in a first gas permeable container containing cell medium
therein; obtaining tumor infiltrating lymphocytes (TIL) from the
tumor tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells;
and administering the expanded number of TIL to the mammal.
[0004] Another embodiment of the invention provides a method of
obtaining an expanded number of TIL from a mammal for adoptive cell
immunotherapy comprising obtaining a tumor tissue sample from the
mammal; culturing the tumor tissue sample in a first gas permeable
container containing cell medium therein; obtaining TIL from the
tumor tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder
cells.
[0005] Still another embodiment of the invention provides a method
of obtaining an expanded number of TIL from a mammal for adoptive
cell immunotherapy comprising obtaining a tumor tissue sample from
the mammal; obtaining TIL from the tumor tissue sample; expanding
the number of TIL in a gas permeable container containing cell
medium therein using irradiated allogeneic feeder cells and/or
irradiated autologous feeder cells.
[0006] Another embodiment of the invention provides a method of
promoting regression of cancer in a mammal comprising obtaining a
tumor tissue sample from the mammal; obtaining TIL from the tumor
tissue sample; expanding the number of TIL in a gas permeable
container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells;
and administering the expanded number of TIL to the mammal.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0007] FIG. 1A is a graph showing the numbers of TIL produced by 10
tumor fragments from eight tumor samples in 24-well plates
(diamonds) and G-Rex10 flasks (squares). For each individual tumor
sample, 10 fragments were seeded into a 24-well plate at 1 piece
per well and 10 fragments were seeded into a single G-Rex 10 flask.
Cells were harvested by 7 to 23 days of culture, pooled if
collected from 24-well plate, and counted. A total of 8 samples
were tested.
[0008] FIG. 1B is a graph showing the number of TIL produced per
each tumor fragment by 7 to 23 days of culture of 5, 10, 20 and 30
tumor fragments in G-Rex10 flasks. Because only G-Rex10 flasks with
10 fragments were used in all experiments, the data were normalized
using the number of cells produced in G-Rex10 flasks with 10
fragments. The number of TIL produced in each flask was divided by
the number of fragments in the flask and this value was divided by
the number of TIL produced in G-Rex10 flasks with 10 fragments from
the same patient divided by 10. The average number of TIL produced
by each tumor fragment in G-Rex10 flasks seeded with 10 fragments
was 7.51.times.10.sup.6 cells per fragment (n=11).
[0009] FIG. 1C is a graph showing the total number of TIL produced
by 7 to 23 days of culture of 5, 10, 20 and 30 tumor fragments in
G-Rex10 flasks. The data were normalized using the number of cells
produced in G-Rex10 flasks with 10 fragments. The total number TIL
produced in each G-Rex10 flask was divided by the number of TIL
produced by each G-Rex10 flask seeded with 10 tumor fragments from
the same patient. The average number of TIL produced by G-Rex10
flasks seeded with 10 tumor fragments was 75.1.times.10.sup.6
(n=11).
DETAILED DESCRIPTION OF THE INVENTION
[0010] An embodiment of the invention provides a method of
promoting regression of cancer in a mammal comprising obtaining a
tumor tissue sample from the mammal; culturing the tumor tissue
sample in a first gas permeable container containing cell medium
therein; obtaining tumor infiltrating lymphocytes (TIL) from the
tumor tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells;
and administering the expanded number of TIL to the mammal.
[0011] The inventive methods provide numerous advantages. For
example, methods of promoting regression of cancer and obtaining an
expanded number of TIL using gas permeable containers are simpler,
less labor-intensive, use less reagents, and can be performed using
simpler equipment than procedures using non-gas permeable
containers (e.g., T-flasks (e.g., T-175 flasks), bags, and
multi-well plates). In addition, gas permeable containers may
advantageously protect the cells from microbial contamination more
effectively than non-gas permeable containers which may be "open"
systems. In addition, methods using gas permeable containers may
advantageously reduce the number of containers that are used
compared to methods using non-gas permeable containers, thereby
reducing the amount of labor necessary to carry out the methods and
also reducing the risk of microbial contamination. Thus, producing
cells in gas permeable containers may be more suitable for
compliance with the current manufacturing practice (cGMP)
conditions that are required for, e.g., Phase III clinical trials.
Moreover, methods using gas-permeable containers advantageously
reduce the final culture volume to lower than that obtained with
non-gas permeable containers, which advantageously lowers the
incubator capacity required to grow the cells, reduces the amount
of reagents (e.g., cell culture medium and additives) necessary to
grow the cells, and simplifies the equipment and/or procedures for
concentrating and washing the cells. Another advantage of the
inventive methods is that the cells may be fed less frequently in
gas-permeable containers (e.g., about every three to four days)
than in non-gas permeable containers (e.g., every other day),
particularly when the cells and/or tumor tissue sample are cultured
submerged under at least about 1.3 cm of cell culture medium in a
gas permeable container. Moreover, cells in gas permeable
containers may be handled less frequently than cells in non-gas
permeable containers (e.g., bags), which may minimize disturbance
of the tumor fragment and provide more reproducible TIL growth. In
addition, one or more aspects (e.g., but not limited to, culturing
and/or expanding) of the inventive methods may be automatable. The
development of a simpler, less expensive, and less labor-intensive
method to generate clinically effective TIL is believed to
advantageously aid in the more widespread use of adoptive cell
therapy and permit the delivery of therapeutically effective TIL to
more patients in a shorter time period. Faster and more efficient
adoptive cell therapy may allow patients to be treated more quickly
when the disease is at an earlier, less progressive stage, which
increases the likelihood that more patients will respond positively
to treatment. The inventive methods may also make it possible to
treat certain patients who previously may not have been
successfully treated because sufficient numbers of TIL were not
generated due to the technical and logistical complexities of
methods that do not use gas permeable flasks. Accordingly, the
inventive methods advantageously may make it possible to treat or
prevent a wider variety of cancers and, therefore, treat a larger
number of patients.
[0012] The method comprises obtaining a tumor tissue sample from
the mammal. The tumor tissue sample can be obtained from numerous
sources, including but not limited to tumor biopsy or necropsy. The
tumor tissue sample may be obtained from any cancer, including but
not limited to any of the cancers described herein. Preferably, the
cancer is melanoma. The tumor tissue sample may be obtained from
any mammal. Preferably, the tumor tissue sample is obtained from a
human. In an embodiment, the tumor tissue sample may be a tumor
tissue fragment. The tumor tissue sample may be fragmented, e.g.,
by dissection, to provide a tumor tissue fragment. Alternatively or
additionally, the tumor tissue sample may, optionally, be
enzymatically or mechanically digested. Suitable enzymes for
fragmenting the tumor tissue sample include, but are not limited
to, collagenase. In an embodiment, the tumor tissue sample is
fragmented without digestion. The tumor tissue fragment may be any
suitable size. Preferably, the tumor tissue fragment has a size of
about 1 mm.sup.3 or less to about 8 mm.sup.3 or larger, about 1
mm.sup.3 to about 4 mm.sup.3, about 1 mm.sup.3 to about 2 mm.sup.3,
or about 1 mm.sup.3.
[0013] The method further comprises culturing the tumor tissue
sample in a first gas permeable container containing cell medium
therein. In an embodiment, the tumor tissue sample is cultured
directly on the gas permeable material in the gas permeable
container without digestion. In another embodiment, an
enzymatically or mechanically digested tumor tissue sample may be
cultured directly on the gas permeable material. Any suitable cell
medium may be used. The cell culture medium may further comprise
any suitable T-cell growth factor such as, e.g., interleukin
(IL)-2. The cell culture medium may optionally further comprise
human AB serum. The tumor tissue sample may contain TIL that are
autologous to the patient. Culturing the tumor tissue sample may
include culturing the TIL present in the tumor sample.
[0014] The method also comprises obtaining TIL from the tumor
tissue sample. The tumor tissue sample comprises TIL. As the tumor
tissue sample is cultured in the gas permeable container, e.g., on
gas permeable material in the container, TIL present in the tumor
tissue sample also begin to grow in the gas permeable container,
e.g., on the gas permeable material. TIL may be obtained from the
tumor tissue sample in any suitable manner.
[0015] The first gas permeable container may be any suitable gas
permeable container. In an embodiment of the invention, the first
gas permeable container comprises a base, sides, and a cap. The
container, preferably the base, may comprise a gas permeable
support and a gas permeable material, e.g., a gas permeable
membrane. The gas permeable material may be positioned inside the
container directly on the gas permeable support which comprises
openings (e.g., channels) in fluid communication with ambient gas
in order to facilitate gas exchange between the interior of the
container and the ambient gas. The cap may comprise a vent and/or a
port (e.g., an access port). In a preferred embodiment, the access
port may have an opening greater than about 1 mm to about 1 cm
(e.g., greater than about 1 mm or greater than about 1 cm). An
access port with an opening greater than about 1 mm to about 1 cm
may advantageously eliminate or reduce disturbance of the TIL. In
an embodiment, the gas permeable container may comprise a vent or a
vented port, which may be advantageous in the event that the
temperature in the container drops during handling. Preferably the
first gas permeable container is a gas permeable container as
described in U.S. Patent Application Publication No. 2005/0106717,
which is incorporated herein by reference, and commercially
available from Wilson Wolf Manufacturing Corporation (e.g.,
G-Rex10, GP200, G-Rex100, GP2000 containers) (New Brighton,
Minn.).
[0016] The first gas permeable container may have any suitable cell
medium volume capacity. For example, the first gas permeable
container may have a medium volume capacity of about 40 mL or more;
about 200 mL or more; about 500 mL or more; about 2,000 mL or more;
or about 5,000 mL or more. Although the first gas permeable
container may have any suitable medium volume capacity, the tumor
tissue sample and/or TIL may be cultured in any suitable volume of
medium. Preferably, the tumor tissue sample and/or TIL are cultured
submerged under a height of at least about 1.3 cm of cell culture
medium. More preferably, the tumor tissue sample and/or TIL are
cultured submerged under a height of at least about 2.0 cm of cell
culture medium. Tumor tissue samples and/or TIL cultured on a gas
permeable material submerged under a height of at least about 1.3
cm or a height of at least about 2.0 cm of medium may,
advantageously, be handled and fed less frequently.
[0017] In addition, the first gas permeable container may provide
any suitable surface area for the growth of the TIL. For example,
the gas permeable container may have a surface area for growth of
the TIL of about 10 cm.sup.2 or more; about 100 cm.sup.2 or more;
or about 650 cm.sup.2 or more.
[0018] In use, the tumor tissue sample and/or TIL are cultured
inside the first gas permeable container in contact with the gas
permeable material and submerged under a suitable volume of culture
medium. Culturing the tumor tissue sample and/or TIL in contact
with the gas permeable material facilitates gas exchange between
the cells and the ambient air. Facilitating gas exchange between
the cells and the ambient air facilitates the respiration, growth,
and viability of the cells. Moreover, the gas exchange across the
gas permeable material can facilitate circulation of the medium
(e.g., by convection and diffusion) within the container, which
facilitates feeding of the TIL.
[0019] The method further comprises expanding the number of TIL in
a second gas permeable container containing cell medium therein
using irradiated allogeneic feeder cells and/or irradiated
autologous feeder cells. In an embodiment, the number of TIL is
expanded using a ratio of about 1 TIL to at least about 20 feeder
cells, about 1 TIL to at least about 25 feeder cells, about 1 TIL
to at least about 50 feeder cells, about 1 TIL to at least about
100 feeder cells, about 1 TIL to at least about 200 feeder cells,
e.g., a TIL-to-feeder cell ratio of about 1 to about 20, about 1 to
about 25, about 1 to about 50, about 1 to about 100, or about 1 to
about 200. The second gas permeable container may be as described
for the first container.
[0020] The cultured TIL are expanded, preferably, rapidly expanded.
Rapid expansion provides an increase in the number of TIL of at
least about 50-fold (or 60-, 70-, 80-, 90-, or 100-fold, or
greater) over a period of about 10 to about 14 days, preferably
about 14 days. More preferably, rapid expansion provides an
increase of at least about 200-fold (or 300-, 400-, 500-, 600-,
700-, 800-, 900-, or greater) over a period of about 10 to about 14
days, preferably about 14 days. Most preferably, rapid expansion
provides an increase of at least about 1000-fold over a period of
about 10 to about 14 days, preferably about 14 days. Preferably,
rapid expansion provides an increase of about 1000-fold to about
2000-fold, e.g., about 1000-fold, about 1500-fold, or about
2,000-fold over a period of about 14 days.
[0021] Expansion can be accomplished in the gas permeable container
by any suitable method. For example, TIL can be rapidly expanded
using non-specific T-cell receptor stimulation in the presence of
feeder cells (e.g., irradiated allogeneic feeder cells, irradiated
autologous feeder cells, and/or artificial antigen presenting cells
(e.g., K562 leukemia cells transduced with nucleic acids encoding
CD3 and/or CD8)) and either interleukin-2 (IL-2) or interleukin-15
(IL-15), with IL-2 being preferred. In an embodiment of the method,
expanding the number of TIL uses about 1.times.10.sup.9 to about
4.times.10.sup.9 allogeneic feeder cells and/or autologous feeder
cells, preferably about 2.times.10.sup.9 to about 3.times.10.sup.9
allogeneic feeder cells and/or autologous feeder cells. The
non-specific T-cell receptor stimulus can include, for example,
about 30 ng/ml of OKT3, a mouse monoclonal anti-CD3 antibody
(available from ORTHO-MCNEIL, Raritan, N.J. or MILTENYI BIOTECH,
Auburn, Calif.). Alternatively, TIL can be rapidly expanded by, for
example, stimulation of the TIL in vitro with an antigen (one or
more, including antigenic portions thereof, such as epitope(s), or
a cell) of the cancer, which can be optionally expressed from a
vector, such as an human leukocyte antigen A2 (HLA-A2) binding
peptide, e.g., 0.3 .mu.M MART-1:26-35 (27L) or gp100:209-217
(210M), in the presence of a T-cell growth factor, such as 300
IU/ml IL-2 or IL-15, with IL-2 being preferred. Other suitable
antigens may include, e.g., NY-ESO-1, TRP-1, TRP-2, tyrosinase
cancer antigen, MAGE-A3, SSX-2, and VEGFR2, or antigenic portions
thereof. The in vitro-induced TIL are rapidly expanded by
re-stimulation with the same antigen(s) of the cancer pulsed onto
HLA-A2-expressing antigen-presenting cells. Alternatively, the TIL
can be re-stimulated with, for example, irradiated, autologous
lymphocytes or with irradiated HLA-A2+ allogeneic lymphocytes and
IL-2, for example.
[0022] In an embodiment, expanding the number of TIL may comprise
using about 5,000 mL to about 10,000 mL of cell medium, preferably
about 5,800 mL to about 8,700 mL of cell medium. In an embodiment,
expanding the number of TIL uses no more than one type of cell
culture medium. Any suitable cell culture medium may be used, e.g.,
AIM-V cell medium (L-glutamine, 50 .mu.g/ml streptomycin sulfate,
and 10 .mu.g/ml gentamicin sulfate) cell culture medium
(Invitrogen, Carlsbad Calif.). In this regard, the inventive
methods advantageously reduce the amount of medium and the number
of types of medium required to expand the number of TIL.
[0023] In an embodiment, expanding the number of TIL may comprise
feeding the cells no more frequently than every third or fourth
day. Expanding the number of cells in a gas permeable container
advantageously simplifies the procedures necessary to expand the
number of cells by reducing the feeding frequency necessary to
expand the cells.
[0024] In an embodiment, the cell medium in the first and/or second
gas permeable container is unfiltered. Without being bound to a
particular theory, it is believed that particulate serum components
present in some cell medium supplements (e.g., AB serum) have
little or no detrimental effects on TIL growth. The use of
unfiltered cell medium may, advantageously, simplify the procedures
necessary to expand the number of cells.
[0025] In an embodiment, the cell medium in the first and/or second
gas permeable container lacks beta-mercaptoethanol (BME). The
absence of BME from the cell medium may be advantageously more
compliant with cGMP and, thus, may advantageously make it easier to
gain regulatory approval.
[0026] In an embodiment, the duration of the method comprising
obtaining a tumor tissue sample from the mammal; culturing the
tumor tissue sample in a first gas permeable container containing
cell medium therein; obtaining TIL from the tumor tissue sample;
expanding the number of TIL in a second gas permeable container
containing cell medium therein using irradiated allogeneic feeder
cells and/or irradiated autologous feeder cells may be about 28 to
about 42 days, e.g., about 28 days.
[0027] The method comprises administering the expanded TIL to the
mammal. The TIL can be administered by any suitable route as known
in the art. Preferably, the TIL are administered as an
intra-arterial or intravenous infusion, which preferably lasts
about 30 to about 60 minutes. Other examples of routes of
administration include intraperitoneal, intrathecal and
intralymphatic.
[0028] Likewise, any suitable dose of TIL can be administered.
Preferably, from about 1.0.times.10.sup.10 TIL to about
13.7.times.10.sup.10 TIL are administered, with an average of
around 5.0.times.10.sup.10 TIL, particularly if the cancer is
melanoma. Alternatively, from about 1.2.times.10.sup.10 to about
4.3.times.10.sup.10 TIL are administered.
[0029] In addition to TIL, macrophages, monocytes, and natural
killer (NK) cells may also be obtained from the tumor tissue
sample, cultured, and expanded as described herein for TIL.
Accordingly, the method may also comprise administering
macrophages, monocytes, and natural killer (NK) cells to the
mammal. The inventive methods may also be effective for expanding
NK cells.
[0030] In an embodiment of the method, a T-cell growth factor that
promotes the growth and activation of the TIL is administered to
the mammal either concomitantly with the TIL or subsequently to the
TIL. The T-cell growth factor can be any suitable growth factor
that promotes the growth and activation of the TIL. Examples of
suitable T-cell growth factors include interleukin (IL)-2, IL-7,
IL-15, and IL-12, which can be used alone or in various
combinations, such as IL-2 and IL-7, IL-2 and IL-15, IL-7 and
IL-15, IL-2, IL-7 and IL-15, IL-12 and IL-7, IL-12 and IL-15, or
IL-12 and IL-2. IL-2 is a preferred T-cell growth factor.
[0031] In an embodiment of the method, the TIL are modified to
express a T-cell growth factor that promotes the growth and
activation of the TIL. Suitable T-cell growth factors include, for
example, any of those described above. Suitable methods of
modification are known in the art. See, for instance, Sambrook et
al., Molecular Cloning: A Laboratory Manual, 3.sup.rd ed., Cold
Spring Harbor Press, Cold Spring Harbor, N.Y. 2001; and Ausubel et
al., Current Protocols in Molecular Biology, Greene Publishing
Associates and John Wiley & Sons, NY, 1994. Desirably, modified
TIL express the T-cell growth factor at high levels. T-cell growth
factor coding sequences, such as that of IL-12, are readily
available in the art, as are promoters, the operable linkage of
which to a T-cell growth factor coding sequence promote high-level
expression. In an embodiment, the TIL may be modified to express
IL-12 as described in World Intellectual Property Organization
Patent Application Publication No. WO 2010/126766, which is
incorporated herein by reference.
[0032] In some embodiments, it is believed, two cytokines are more
effective than a single cytokine, and three cytokines, e.g., IL-2,
IL-7 and IL-15, are more effective than any two cytokines. It is
believed that IL-15 enhances a tumor-specific CD8.sup.+ T-cell
response. In this regard, the administration of IL-15-cultured
cells with IL-2 (such as a bolus injection) can be particularly
efficacious. In another embodiment, TIL modified to express IL-12
may be administered with IL-2 as a bolus injection.
[0033] The T-cell growth factor can be administered by any suitable
route. If more than one T-cell growth factor is administered, they
can be administered simultaneously or sequentially, in any order,
and by the same route or different routes. Preferably, the T-cell
growth factor, such as IL-2, is administered intravenously as a
bolus injection. Desirably, the dosage of the T-cell growth factor,
such as IL-2, is what is considered by those of ordinary skill in
the art to be high. Preferably, a dose of about 720,000 IU/kg of
IL-2 is administered three times daily until tolerance,
particularly when the cancer is melanoma. Preferably, about 5 to
about 15 doses of IL-2 are administered, with an average of around
8 doses.
[0034] TIL can recognize any of the unique antigens produced as a
result of the estimated 10,000 genetic mutations encoded by each
tumor cell genome. The antigen, however, need not be unique. TIL
can recognize one or more antigens of a cancer, including an
antigenic portion of one or more antigens, such as an epitope, or a
cell of the cancer. An "antigen of a cancer" and an "antigen of the
cancer" are intended to encompass all of the aforementioned
antigens. If the cancer is melanoma, such as metastatic melanoma,
preferably the TIL recognize MART-1 (such as MART-1:26-35 (27L)),
gp100 (such as gp100:209-217 (210M)), or a "unique" or
patient-specific antigen derived from a tumor-encoded mutation.
Other suitable melanoma antigens which may be recognized by TIL can
include, but are not limited to, tyrosinase, tyrosinase related
protein (TRP)1, TRP2, and MAGE. TIL can also recognize antigens
such as, for example, NY-ESO-1, telomerase, p53, HER2/neu,
carcinoembryonic antigen, or prostate-specific antigen, for
treatment of lung carcinoma, breast cancer, colon cancer, prostate
cancer, and the like.
[0035] In an embodiment of the method, the TIL are modified to
express a T cell receptor (TCR) having antigenic specificity for a
cancer antigen, e.g., any of the cancer antigens described herein.
Suitable TCRs include, for example, those with antigenic
specificity for a melanoma antigen, e.g., gp100 or MART-1. Suitable
methods of modification are known in the art. See, for instance,
Sambrook and Ausubel, supra. For example, the TIL may be transduced
to express a T cell receptor (TCR) having antigenic specificity for
a cancer antigen using transduction techniques described in Morgan
et al., Science 314(5796):126-9 (2006) and Johnson et al. Blood
114:535-46 (2009).
[0036] The cancer can be any cancer, including any of acute
lymphocytic cancer, acute myeloid leukemia, alveolar
rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer
of the anus, anal canal, or anorectum, cancer of the eye, cancer of
the intrahepatic bile duct, cancer of the joints, cancer of the
neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or
middle ear, cancer of the oral cavity, cancer of the vulva, chronic
lymphocytic leukemia, chronic myeloid cancer, colon cancer,
esophageal cancer, cervical cancer, gastrointestinal carcinoid
tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer,
larynx cancer, liver cancer, lung cancer, malignant mesothelioma,
melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin
lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum,
and mesentery cancer, pharynx cancer, prostate cancer, rectal
cancer, renal cancer, skin cancer, small intestine cancer, soft
tissue cancer, stomach cancer, testicular cancer, thyroid cancer,
ureter cancer, and urinary bladder cancer. A preferred cancer is
melanoma. A particularly preferred cancer is metastatic
melanoma.
[0037] As used herein, the term "mammal" refers to any mammal,
including, but not limited to, mammals of the order Rodentia, such
as mice and hamsters, and mammals of the order Logomorpha, such as
rabbits. It is preferred that the mammals are from the order
Carnivora, including Felines (cats) and Canines (dogs). It is more
preferred that the mammals are from the order Artiodactyla,
including Bovines (cows) and Swines (pigs) or of the order
Perssodactyla, including Equines (horses). It is most preferred
that the mammals are of the order Primates, Ceboids, or Simoids
(monkeys) or of the order Anthropoids (humans and apes). An
especially preferred mammal is the human.
[0038] Promoting regression of cancer in a mammal may comprise
treating or preventing cancer in the mammal. The terms "treat,"
"prevent," and "regression," as well as words stemming therefrom,
as used herein, does not necessarily imply 100% or complete
regression. Rather, there are varying degrees of treatment,
prevention, and regression of which one of ordinary skill in the
art recognizes as having a potential benefit or therapeutic effect.
In this respect, the inventive methods can provide any amount of
any level of treatment, prevention, or regression of cancer in a
mammal. Furthermore, the treatment, prevention, or regression
provided by the inventive method can include treatment, prevention,
or regression of one or more conditions or symptoms of the disease,
e.g., cancer. Also, for purposes herein, "treatment," "prevention,"
and "regression" can encompass delaying the onset of the disease,
or a symptom or condition thereof.
[0039] Another embodiment provides a method of obtaining an
expanded number of TIL from a mammal for adoptive cell
immunotherapy comprising obtaining a tumor tissue sample from the
mammal; culturing the tumor tissue sample in a first gas permeable
container containing cell medium therein; obtaining TIL from the
tumor tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder
cells.
[0040] The method comprises obtaining a tumor tissue sample from
the mammal. The tumor tissue sample may be obtained as described
herein with respect to any embodiments of the invention.
[0041] The method comprises culturing the tumor tissue sample in a
first gas permeable container containing cell medium therein. The
tumor tissue sample may be cultured in a first gas permeable
container as described herein with respect to any embodiments of
the invention.
[0042] The method comprises obtaining TIL from the tumor tissue
sample. The TIL may be obtained from the tumor tissue sample as
described herein with respect to any embodiments of the
invention.
[0043] The method comprises expanding the number of TIL in a second
gas permeable container containing cell medium therein using
irradiated allogeneic feeder cells and/or irradiated autologous
feeder cells. The number of TIL may be expanded as described herein
with respect to any embodiments of the invention.
[0044] Still another embodiment of the invention provides a method
of obtaining an expanded number of TIL from a mammal for adoptive
cell immunotherapy comprising obtaining a tumor tissue sample from
the mammal; obtaining TIL from the tumor tissue sample; expanding
the number of TIL in a gas permeable container containing cell
medium therein using irradiated allogeneic feeder cells and/or
irradiated autologous feeder cells. Obtaining a tumor tissue sample
from the mammal, obtaining TIL from the tumor tissue sample, and
expanding the number of TIL in a second gas permeable container
containing cell medium therein using irradiated allogeneic feeder
cells and/or irradiated autologous feeder cells may be carried out
as described herein with respect to any embodiments of the
invention.
[0045] The method may further comprise culturing the tumor tissue
by any suitable method that facilitates the obtaining of TIL from
the tumor tissue sample. In this regard, culturing the tumor tissue
may comprise establishing multiple independent cultures, e.g.,
microcultures. For example, culturing the tumor tissue may comprise
culturing tumor fragments in plates, e.g., 24-well plates. In an
embodiment, the tumor tissue is cultured without a gas permeable
container.
[0046] In some embodiments, the method further comprises selecting
TIL capable of lysing cancer cells while in other embodiments, the
method does not include selecting TIL capable of lysing cancer
cells. TIL capable of lysing cancer cells may be selected by
identifying TILs having any suitable trait associated with the
lysis of cancer cells and/or the regression of cancer. Exemplary
suitable TIL traits that may serve as the basis for selecting TILs
may include any one or more of IFN-.gamma. release upon co-culture
with autologous tumor cells; cell surface expression of one or more
of CD8, CD27, and CD28; and telomere length. Without being bound to
a particular theory, it is believed that cell surface expression of
one or more of CD8, CD27, and CD28 and longer telomere lengths are
associated with positive objective clinical responses in patients
and persistence of the cells in vivo. Preferably the trait is
IFN-.gamma. release upon co-culture with autologous tumor cells. In
an embodiment of the invention, selected TIL release about 200
pg/ml or more of IFN-.gamma. upon co-culture with tumor cells.
[0047] In some embodiments, selecting TIL capable of lysing cancer
cells comprises testing individual cultures for presence of the
trait and identifying TIL possessing the trait. Methods of testing
cultures for the presence of any one or more of IFN-.gamma. release
upon co-culture with autologous tumor cells; cell surface
expression of one or more of CD8, CD27, and CD28; and telomere
length (longer telomeres being associated with regression of
cancer) are known in the art.
[0048] Any number of cultures may be selected. For example, one,
two, three, four, five, or more cultures may be selected. In
embodiments in which two or more cultures are selected, the
selected cultures may be combined and the number of TIL expanded in
one (or more) gas permeable containers. Preferably, however, in
embodiments in which two or more cultures are selected, each
selected culture is separately expanded in separate gas permeable
containers. Without being bound to a particular theory, it is
believed that expanding multiple selected cultures separately
advantageously increases lymphocyte diversity for patient
treatment.
[0049] The method may further comprise expanding the number of TIL
in an identified culture in a second gas permeable container
containing cell medium therein using irradiated allogeneic feeder
cells and/or irradiated autologous feeder cells as described herein
with respect to any embodiments of the invention.
[0050] Another embodiment of the invention provides a method of
promoting regression of cancer in a mammal comprising obtaining a
tumor tissue sample from the mammal; obtaining TIL from the tumor
tissue sample; expanding the number of TIL in a second gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells;
and administering the expanded number of TIL to the mammal.
Obtaining a tumor tissue sample from the mammal, obtaining TIL from
the tumor tissue sample, expanding the number of TIL in a gas
permeable container containing cell medium therein using irradiated
allogeneic feeder cells and/or irradiated autologous feeder cells,
and administering the expanded number of TIL to the mammal may be
carried out as described herein with respect to any embodiments of
the invention. In some embodiments, the method further comprises
selecting TIL capable of lysing cancer cells. The TIL may be
selected as described herein with respect to any embodiments of the
invention.
[0051] The following examples further illustrate the invention but,
of course, should not be construed as in any way limiting its
scope.
EXAMPLES
Initial TIL Culture
[0052] Patients were entered into clinical protocols and signed
informed consents that were approved by the Institutional Review
Board of the National Cancer Institute prior to tumor resection.
TIL were initially cultured from enzymatic tumor digests and tumor
fragments (about 1 to about 8 mm.sup.3) produced by sharp
dissection. Tumor digests were generated by incubation in enzyme
media (Roswell Park Memorial Institute (RPMI) 1640, 2 mM glutamate,
10 mcg/mL gentamicine, 30 units/mL of DNase and 1.0 mg/mL of
collagenase) followed by mechanical dissociation (GentleMACS.TM.
dissociator, Miltenyi Biotec, Auburn, Calif.). In brief,
immediately after placing the tumor in enzyme media the tumor was
mechanically dissociated for approximately 1 minute. The solution
was then incubated for 30 minutes at 37.degree. C. in 5% CO.sub.2
and was then mechanically disrupted again approximately 1 minute.
After being incubated again for 30 minutes at 37.degree. C. in 5%
CO.sub.2, the tumor was mechanically disrupted a third time for
approximately one minute. If after the third mechanical disruption,
large pieces of tissue were present, one or two additional
mechanical dissociations were applied to the sample, with or
without 30 additional minutes of incubation at 37.degree. C. in 5%
CO.sub.2. At the end of the final incubation, if the cell
suspension contained a large number of red blood cells or dead
cells, a density gradient separation using FICOLL branched
hydrophilic polysaccharide (GE Healthcare, Smyrna, Ga.) was
preformed to remove these cells.
[0053] TIL growth from digests and fragments were initiated in
either gas permeable flasks with a 40 mL volume and a 10 cm.sup.2
gas-permeable silicon bottom (G-Rex10, Wilson Wolf Manufacturing,
New Brighton, Minn., USA) or 24-well plates (Corning Corning,
N.Y.). When TIL cultures were initiated in 24-well plates (COSTAR
24-well cell culture cluster, flat bottom, Corning Incorporated,
Corning, N.Y.), each well was seeded with 1.times.10.sup.6 tumor
digest cells or one tumor fragment approximately 1 to 8 mm.sup.3 in
size in 2 mL of CM with IL-2 (6000 IU/mL, Chiron Corp., Emeryville,
Calif.). CM included RPMI 1640 with glutamine, supplemented with
10% AB serum, 25 mM Hepes and 10 .mu.g/ml gentamicin. When cultures
were initiated in G-Rex10 flasks, each flask was loaded with 10 to
40.times.10.sup.6 viable tumor digest cells or 5 to 30 tumor
fragments in 10 to 40 ml of CM with IL-2. Both the G-Rex10 and
24-well plates were incubated in a humidified incubator at
37.degree. C. in 5% CO.sub.2 and five days after culture
initiation, half the media was removed and replaced with fresh CM
and IL-2 and after day 5, half the media was changed every 2 to 3
days.
TIL Rapid Expansion Protocol (REP)
[0054] REP of TIL was performed using T-175 flasks and gas
permeable bags as previously described (Tran et al., J. Immunother.
31(8):742-51 (2008); Dudley et al., J. Immunother. 26(4):332-42
(2003)) or gas permeable cultureware (G-Rex flasks). For TIL REP in
T-175 flasks, 1.times.10.sup.6 TIL suspended in 150 ml of media was
added to each T-175 flask. The TIL were cultured with irradiated
(50 Gy) allogeneic peripheral blood mononuclear cells (PBMC) as
"feeder" cells at a ratio of 1 TIL to 100 feeder cells and the
cells were cultured in a 1 to 1 mixture of CM and AIM-V medium,
supplemented with 3000 IU per mL of IL-2 and 30 ng per ml of
anti-CD3. The T-175 flasks were incubated at 37.degree. C. in 5%
CO.sub.2. Half the media was exchanged on day 5 using 50/50 medium
with 3000 IU per mL of IL-2. On day 7 cells from two T-175 flasks
were combined in a 3 liter bag and 300 mL of AIM V with 5% human AB
serum and 3000 IU per mL of IL-2 was added to the 300 ml of TIL
suspension. The number of cells in each bag was counted every day
or two and fresh media was added to keep the cell count between 0.5
and 2.0.times.10.sup.6 cells/mL.
[0055] For TIL REP in 500 mL capacity gas permeable flasks with 100
cm.sup.2 gas-permeable silicon bottoms (G-Rex100, commercially
available from Wilson Wolf Manufacturing Corporation, New Brighton,
Minn., USA), 5.times.10.sup.6 or 10.times.10.sup.6 TIL were
cultured with irradiated allogeneic PBMC at a ratio of 1 to 100 in
400 mL of 50/50 medium, supplemented with 5% human AB serum, 3000
IU per mL of IL-2 and 30 ng per ml of anti-CD3. The G-Rex100 flasks
were incubated at 37.degree. C. in 5% CO.sub.2. On day 5, 250 mL of
supernatant was removed and placed into centrifuge bottles and
centrifuged at 1500 rpm (491.times.g) for 10 minutes. The TIL
pellets were re-suspended with 150 mL of fresh medium with 5% human
AB serum, 3000 IU per mL of IL-2, and added back to the original
G-Rex100 flasks. When TIL were expanded serially in G-Rex100
flasks, on day 7 the TIL in each G-Rex100 were suspended in the 300
mL of media present in each flask and the cell suspension was
divided into 3 100 mL aliquots that were used to seed 3 G-Rex100
flasks. Then 150 mL of AIM-V with 5% human AB serum and 3000 IU per
mL of IL-2 was added to each flask. The G-Rex100 flasks were
incubated at 37.degree. C. in 5% CO.sub.2 and after 4 days 150 mL
of AIM-V with 3000 IU per mL of IL-2 was added to each G-Rex100
flask. The cells were harvested on day 14 of culture.
Cell Counts, Viability, Flow Cytometery
[0056] The expression of CD3, CD4, CD8 and CD56 was measured by
flow cytometry with antibodies from BD Biosciences (BD Biosciences,
San Jose, Calif.) using a FACSCanto.TM. flow cytometer (BD
Biosciences). The cells were counted manually using a disposable
hemacytometer and viability was assessed using trypan blue
staining.
Cyokine Release Assays
[0057] TIL were evaluated for interferon-gamma (IFN-.gamma.)
secretion in response to stimulation either with OKT3 antibody or
co-culture with autologous tumor digest. For OKT3 stimulation, TIL
were washed extensively, and duplicate wells were prepared with
1.times.10.sup.5 cells in 0.2 ml CM in 96 well flat-bottom plates
pre-coated with 0.1 or 1.0 .mu.g/mL of OKT-3 antibody diluted in
PBS. After overnight incubation, the supernatants were harvested
and IFN-.gamma. in the supernatant was measured by ELISA
(Pierce/Endogen, Woburn, Mass.). For the co-culture assay, TIL
cells were placed into a 96-well plate with autologous tumor cells.
After a 24 hour incubation, supernatants were harvested and
IFN-.gamma. release was quantified by ELISA.
Statistical Analysis
[0058] Values are mean one.+-.standard error of the mean (SEM)
unless otherwise indicated. Groups were compared using paired T
tests.
Example 1
[0059] This example demonstrates that TIL cultured in gas-permeable
containers is better than, or at least comparable to, that in a
24-well plate.
[0060] The growth of TIL from tumors using gas permeable flasks
with a 40 mL capacity and 10 cm.sup.2 gas permeable silicone bottom
(G-Rex10, Wilson Wolf Manufacturing Corporation, New Brighton,
Minn., USA (providing about 10 cm.sup.2 of surface area for growth
of the TIL)) or 24-well plates (Corning Corning, N.Y.) was
compared. A total of 14 melanoma samples were tested, including 9
freshly prepared tumor digests (Table 1A) and 5 thawed samples from
previously frozen tumor digests (Table 1B). TIL from frozen tumor
from patient 2653 were not able to be cultured in either the
G-Rex10 or 24-well plates. Except for one fresh sample (#3522), the
ratio of harvested TIL to initially seeded cells at day 17 to 29
was similar to or better in the G-Rex10 flasks than in the 24-well
plate (Table 1A and 1B).
TABLE-US-00001 TABLE 1A Comparison of initial TIL culture in
G-Rex10flasks with 24-well plates using fresh tumor digests Ratio
of # TIL TIL Phenotype harvested/ (% expressing # cell seeded TIL
Viability (%) CD3+CD8+) Sample 24-well 24-well 24-well Type Patient
# plate G-Rex10 plate G-Rex10 plate G-Rex10 Fresh 3520 1.28 1.17
92.80 93.30 26.50 31.60 Tumor 3522 2.14 1.46 92.10 95.10 39.80
48.70 Digest 3523 2.34 2.30 94.50 93.60 15.00 37.60 3524 1.27 6.22
80.20 95.00 76.70 86.60 3546 5.86 7.60 90.40 93.80 44.60 37.30 3552
3.20 5.83 94.90 97.10 43.10 72.40 3556 3.60 4.15 96.20 96.20 35.40
31.20 3560 6.06 6.25 95.80 97.20 32.30 38.60 3561 4.76 6.38 94.70
93.90 65.80 83.40 Average .+-. SEM 3.39 .+-. 0.61 4.60 .+-. 0.80
92.40 .+-. 1.65 95.02 .+-. 0.50 42.13 .+-. 6.33 51.93 .+-. 7.51
TABLE-US-00002 TABLE 1B Comparison of initial TIL culture in
G-Rex10flasks with 24-well plates using frozen tumor digests Ratio
of # TIL TIL Phenotype harvested/ (% expressing # cell seeded TIL
Viability (%) CD3+CD8+) Sample 24-well 24-well 24-well Type Patient
# plate G-Rex10 plate G-Rex10 plate G-Rex10 Frozen 2653 0.16 0.19
87.70 90.60 N.T. N.T. Tumor 3289 2.43 5.30 95.10 98.00 70.40 73.60
Digest 2976 7.26 7.50 99.00 99.00 66.30 70.00 3071 1.79 6.05 88.40
97.70 37.50 29.10 2998 3.36 5.00 96.30 97.00 64.40 75.80 Average
.+-. SEM 3.00 .+-. 1.18 4.81 .+-. 1.23 93.30 .+-. 2.24 96.46 .+-.
1.50 59.65 .+-. 6.70 62.12 .+-. 9.91 N.T. = Not tested.
[0061] The viability and percentage of cells expressing CD3 and CD8
between these two types of vessels were similar (Tables 1A and 1B).
TIL were obtained from 13 of the 14 samples. These results suggest
that TIL growth in G-Rex10 is better than, or at least comparable
to, that in a 24-well plate.
[0062] IFN-.gamma. production by TIL cultured in G-Rex10 flasks was
also compared with that of TIL cultured in 24-well plates.
IFN-.gamma. production following stimulation with autologous tumor
by TIL from 4 patients cultured in both types of vessels was
similar (Table 1C)
TABLE-US-00003 TABLE 1C Interferon-.gamma. release (pg/ml) by
unstimulated and tumor-stimulated TIL Tumor Target.sup.1 Patient
Growth Method None Allogeneic Autologous 3552 plate 114 157
>1541 G-Rex10 81 338 >1577 3556 plate 90 184 139 G-Rex10 87
363 282 3560 plate 135 175 318 G-Rex10 104 212 572 3561 plate 70 97
207 G-Rex10 84 128 253 .sup.1Cryopreserved enzymatically digested
single cell tumor suspension was thawed and 1 .times. 10.sup.5
viable tumor cells were cocultured with TIL (1:1 ratio) overnight
before quantifying interferon-.gamma. in the supernatant by ELISA.
Values in bold are more than two times background and >200
pg/ml.
Example 2
[0063] This example demonstrates that the culture of TIL from tumor
fragments in gas permeable flasks produces a greater number of TIL
as compared to culture in 24-well plates after 7 to 13 days.
[0064] The growth of TIL from tumor fragments in G-Rex10 flasks or
24-well plates was next compared. For each tumor sample, fragments
approximately 1 to 8 mm.sup.3 in size were seeded into 24-well
plates at 1 piece per well and into G-Rex10 flasks at 5, 10, 20, or
30 pieces per flask. The growth of TIL from 2 lymph nodes and 1
liver metastasis was assessed (Table 2). TIL could be grown from
tumor fragments in both gas-permeable flasks and 24-well plates,
but after 7 to 13 days greater quantities of TIL were obtained from
the G-Rex10 flasks than the wells (Table 2).
TABLE-US-00004 TABLE 2 Initial TIL culture using tumor fragments in
G-Rex10 flasks and 24-well plates. Number of cells Patient # of TIL
Phenotype Number TIL TIL (% TIL expressing each antigen) and Tumor
Culture Tumor TIL# per Viability CD3+ CD3+ Source Vessel Fragments*
(Day 7-13) fragment (%) CD3+ CD4+ CD8+ CD56+ 3581 Wells 1 per well,
5 total 2.71 .times. 10.sup.7 5.42 .times. 10.sup.6 93.2% 53.4%
40.2% 10.3% 11.6% (Lymph G-Rex10 5 fragments 4.29 .times. 10.sup.7
8.58 .times. 10.sup.6 97.0% 61.0% 44.0% 14.3% 7.9% node) G-Rex10 10
fragments 8.02 .times. 10.sup.7 8.02 .times. 10.sup.6 95.4% 58.5%
42.2% 13.7% 9.3% G-Rex10 Dissociated tumor 4.82 .times. 10.sup.7
2.41 .times. 10.sup.6 96.4% 60.3% 40.1% 16.3% 8.9% 3584 Wells 1 per
well, 5 total 1.52 .times. 10.sup.7 3.04 .times. 10.sup.6 92.7%
89.2% 19.8% 68.8% 5.3% (Liver) G-Rex10 5 fragments 4.38 .times.
10.sup.7 8.76 .times. 10.sup.6 95.7% 92.0% 10.6% 81.1% 2.1% G-Rex10
10 fragments 8.13 .times. 10.sup.8 8.13 .times. 10.sup.6 94.4%
91.4% 9.8% 81.2% 2.3% G-Rex10 Dissociated tumor 4.94 .times.
10.sup.7 2.60 .times. 10.sup.6 95.8% 87.7% 11.7% 75.6% 3.3% 3585
Wells 1 per well, 5 total 2.34 .times. 10.sup.7 4.68 .times.
10.sup.6 95.8% 85.5% 14.4% 68.6% 4.20% (Lymph G-Rex10 5 fragments
6.41 .times. 10.sup.7 12.8 .times. 10.sup.6 95.0% 92.1% 20.6% 70.7%
1.10% node) G-Rex10 10 fragments 1.12 .times. 10.sup.8 11.2 .times.
10.sup.6 97.2% 93.4% 18.6% 73.9% 1.30% G-Rex10 Dissociated tumor
3.33 .times. 10.sup.7 1.23 .times. 10.sup.6 90.0% 90.4% 24.0% 65.7%
2.60% *Each tumor fragment was appro.times.imately 1 mm.sup.3.
[0065] A total of 11 tumor samples collected from 9 patients were
tested; 3 samples were from 1 patient, but they were from different
metastatic tumors. TIL could be grown from tumor fragments from all
11 samples in both the G-Rex10 flasks and 24-well plates, but after
7 to 23 days in culture greater quantities of TIL were obtained
from the G-Rex10 flasks. The head-to-head comparison of culturing
10 fragments in the two types of vessels showed that TIL yields
from G-Rex10 flasks were consistently higher than those from
24-well plate (FIG. 1A). The optimal numbers of fragments seeded
into each G-Rex10 flasks was further assessed. The quantities of
TIL obtained per tumor fragment decreased as the number of pieces
added to each G-Rex10 flask increased (FIG. 1B), however, total TIL
yield was higher as more fragments were cultured in the G-Rex10
flasks until 20 or more tumor fragments were cultured in each
G-Rex10 flask (FIG. 1C). The viability of TIL obtained from G-Rex10
flasks was similar to that of TIL obtained from 24-well plates
(96.6.+-.0.6% vs 95.3.+-.0.8%) as was the proportion of TIL
expressing CD3 and CD8 (67.8.+-.7.2% vs 63.3.+-.7.7%). TIL were
also obtained from 3 of the 11 samples by the culture of
mechanically dissociated samples in G-Rex10 flasks, but greater
yields were obtained using tumor fragments as the starting
material.
Example 3
[0066] This example demonstrates the kinetics of TIL growth in
gas-permeable flasks.
[0067] In order to assess the kinetics of TIL growth in
gas-permeable cultureware, TIL from one patient were cultured in
G-Rex100 flasks seeded at a density of 5.times.10.sup.6 and
10.times.10.sup.6 cells per flask. The cells were counted daily
after day 6. On Day 6 the number of cells in the G-Rex100 flask
seeded at 5.times.10.sup.6 cells was 255.times.10.sup.6 cells and
at 10.times.10.sup.6 cells was 300.times.10.sup.6 cells. The
quantity of TIL in G-Rex100 flasks seeded at each cell density
increased steadily until day 9, but there was little increase in
cell counts between days 9 and 10. After 10 days 906.times.10.sup.6
cells were harvested from flasks seeded with 5.times.10.sup.6 TIL
and 1,050.times.10.sup.6 cells from flasks seeded with
10.times.10.sup.6 TIL. Although TIL expanded well for 9 days, in
order to keep the G-Rex100 flask expansion process similar to REP
in T-flasks and gas-permeable bags where TIL are transferred from
T-flasks to bags on day 7, further studies focused on TIL expansion
in the G-Rex100 flasks for 7 days.
Example 4
[0068] This example demonstrates that a 7-day culture of TIL in a
gas permeable container seeded with 10.times.10.sup.6 cells does
not produce a significantly greater number of cells than a gas
permeable container seeded with 5.times.10.sup.6 cells.
[0069] The first step in TIL rapid expansion protocol (REP) has
traditionally been performed in T-175 flasks. The expansion of TIL
in T-175 flasks was compared to expansion in G-Rex100 flasks
(providing about 100 cm.sup.2 of surface area for growth of the
TIL). The expansion of TIL from 4 patients over 7 days in G-Rex100
flasks seeded with 5.times.10.sup.6 and 10.times.10.sup.6 cells was
compared with TIL expansion in T-175 flasks (Table 3). T-175 flasks
were seeded with 1.times.10.sup.6 cells.
TABLE-US-00005 TABLE 3 Comparison of TIL rapid expansion process
(REP) over 7 days in T-175 flasks* and G-Rex100 flasks seeded with
5 .times. 10.sup.6 or 10 .times. 10.sup.6 TIL. Phenotype Fold
Increase Viability (%) (% CD3+CD8+) G- G- G- G- G- G- Rex100 Rex100
Rex100 Rex100 Rex100 Rex100 Patient T-175 5 .times. 10.sup.6 10
.times. 10.sup.6 T-175 5 .times. 10.sup.6 10 .times. 10.sup.6 T-175
5 .times. 10.sup.6 10 .times. 10.sup.6 2812 74 88 57 95.8 96.6 94.7
66.4 64.6 60.5 3289 183 218 139 96.4 94.8 95.1 79.7 83.7 84.1 2976
254 250 ND 94.1 96.1 ND 55.2 59.9 ND 3071 156 146 ND 87.4 90.3 ND
44.6 41.6 ND Mean 167 .+-. 74 176 .+-. 73 98 .+-. 58 93.5 .+-. 2.9
94.5 .+-. 2.9 94.9 .+-. 0.3 61.5 .+-. 15.0 62.5 .+-. 17.3 72.3 .+-.
16.7 *T-175 flasks were seeded with 1 .times. 10.sup.6 TIL.
[0070] After 7 days of culture of TIL from 4 patients, the number
of cells in T-175 flasks increased to 206.+-.103.times.10.sup.6
cells which represented an expansion of 167.+-.74 fold (Table 3).
The culture of TIL from the same 4 patients in G-Rex100 flask
seeded with 5.times.10.sup.6 cells resulted in the production of
877.+-.365.times.10.sup.6 cells which represented an expansion of
176.+-.73 fold. The culture of TIL from 2 of the 4 patients in
G-Rex100 flask seeded with 10.times.10.sup.6 cells resulted in the
production of 980.+-.580.times.10.sup.6 cells which represented an
expansion of 98.+-.58 fold. The viability and proportion of cells
that expressed CD3 and CD8 were similar among those produced by the
three different conditions (Table 3). These results suggest that
the performance of G-Rex100 flasks seeded at the lower seeding
density was comparable to that of the T-175 flasks. Since the 7-day
culture of TIL in G-Rex100 flasks seeded with 10.times.10.sup.6
cells did not produce a significantly greater number of cells than
the G-Rex100 flask seeded with 5.times.10.sup.6 cells, the lower
seeding density was chosen for future experiments.
Example 5
[0071] This example demonstrates that a similar number of cells can
be produced in a 500 mL gas permeable container as compared to a
2000 mL gas permeable container.
[0072] Since the maximum cell yield from one G-Rex100 flask reached
a plateau after approximately 9 days, the production of adequate
quantities of TIL for clinical therapy requires the splitting of
cells during REP and transferring the cells into multiple
gas-permeable flasks for further culture. TIL REP by serial culture
was tested in G-Rex100L, another type of gas-permeable flask that
is commercially available for large scale cell expansion (Wilson
Wolf Manufacturing Corporation, New Brighton, Minn., USA). The
G-Rex100L has the same gas permeable surface area on the silicone
bottom of the flask as the G-Rex100 (providing about 100 cm.sup.2
of surface area for growth of the TIL), but the G-Rex100L is
taller. As a result, the media capacity of the G-Rex100L flask is
approximately 2000 ml compared to approximately 500 mL for the
G-Rex100.
[0073] TIL expansion was compared in these two types of flasks. TIL
were initially seeded at a density of 5.times.10.sup.6 cells for
both the G-Rex100 and G-Rex100L flasks, and were cultured for 7
days as described in Example 3. After 7 days the cells from the
G-Rex100 flask were split into 3 equal parts, and seeded into 3
G-Rex100L flasks. The cells from the G-Rex100L flask were split
into two equal parts, seeded into 2 G-Rex100L flasks. The TIL were
cultured for an additional 7 days in the G-Rex100 and G-Rex100L
flasks.
[0074] The expansion of TIL from two patients was compared in the
G-Rex100 and G-Rex100L flasks. Both patients' TIL growth slowed
after 13 or 14 days. The total number of cells produced after 14
days by culture in the 3 G-Rex100 flasks and the 2 G-Rex100L flasks
was similar for one patient (about 9.times.10.sup.9 cells in
G-Rex100 and G-Rex100L after 14 days) but was greater in the
G-Rex100 flask for the second (about 12.times.10.sup.9 cells in
G-Rex100 and 8.4.times.10.sup.9 cells in G-Rex100L after 14 days)).
Since a similar volume of media is required to produce a similar
number of cells in the G-Rex100 and in the G-Rex100L flasks and
since the G-Rex100 flasks are easier to handle, initial expansion
of TIL in one G-Rex100 flask followed by expansion in 3 G-Rex100
flasks was chosen for future experiments.
Example 6
[0075] This example demonstrates the consistency of serial TIL
expansion using gas permeable containers and a "full scale"
expansion of TIL using gas permeable containers.
[0076] The consistency of serial TIL expansion in G-Rex100 flasks
using cells from 14 patients was tested. Initially,
5.times.10.sup.6 TIL were seeded into a G-Rex100 flask and the
cells were cultured for 7 days. They were then split into 3 equal
parts, seeded into 3 G-Rex100 flasks. After 14 days in culture,
8.60.times.10.sup.9.+-.2.80.times.10.sup.9 TIL with a range of
2.24.times.10.sup.9 to 12.8.times.10.sup.9 were produced. The
number of TIL produced after 14 days was similar for 12 patients,
but lower for two others. When the 2 patients with the lowest
overall TIL expansion were excluded, the mean quantity of TIL
produced was 9.55.times.10.sup.9 cells per original G-Rex100 flask.
The mean cell concentration in G-Rex100 flasks at the end of the
culture was 7.95.times.10.sup.6 cells per mL.
[0077] The IFN-.gamma. release from TIL produced by G-Rex100 REP
and T-175 flask/bag REP was compared. TIL samples produced by both
REP methods using the same tumor samples from 4 patients were
tested. Following stimulation by anti-CD3 IFN-.gamma. production by
TIL expanded in G-Rex100 flasks was similar to that of TIL expanded
in T-175 flasks and bags (Table 4A).
TABLE-US-00006 TABLE 4A IFN-.gamma. release (pg/ml).sup.2
Patient.sup.1 Sample OKT3 1.0 .mu.g/ml OKT3 1.0 .mu.g/ml None 3536
Flask/Bag 631, 672 457, 390 0, 0 G-Rex100 579, 553 243, 277 0, 0
3539 Flask/Bag 12272, 14350 10553, 11039 179, 176 G-Rex100 29792,
29550 26670, 23835 73, 80 3135 Flask/Bag 831, 1124 704, 643 0, 0
G-Rex100 581, 635 151, 74 2, 1 3533 Flask/Bag 6870, 6370 4280, 500
114, 146 G-Rex100 5100, 4510 1513, 1407 136, 150 .sup.1TIL cells
were stimulated by overnight incubation on plate bound OKT3
(anti-CD3 antibody) coated at the concentration indicated.
.sup.2Values are IFN-.gamma. (pg/ml) detected in duplicate wells
measured by ELISA.
[0078] These results suggested that 20 to 30.times.10.sup.9 TIL
could be produced by the initial culture of 15.times.10.sup.6 TIL
in 3 G-Rex100 flasks for 7 days followed by a second 7 day culture
in 9 G-Rex100 flasks (Table 4B).
TABLE-US-00007 TABLE 4B Day 5 Day 11 Day 14 Day 0 Medium Day 7
Media Harvest/ Seeding Change Split (1:3) Addition Wash Con- 3 G- 3
G- 9 G- 9 G- tainers Rex100 Rex100 Rex100 Rex100 Final 400 300 mL
250 mL 400 mL Volume mL/ of container Medium Steps 5 .times.
10.sup.6 Remove 300 mL for 250 mL in TIL are cells TIL 250 mL of
each G- each flask harvested, are media; spin Rex100 is and 150
pooled seeded in down and split into 3 mL new and 400 mL in
resuspend 100 mL media washed each of 3 TIL in 150 aliquots; 100
G-Rex100 mL and mL added to flasks add to 3 G-Rex100 remaining
flasks; an 150 mL additional 150 mL of media is added
[0079] To test this "full scale" G-Rex100 REP, 15.times.10.sup.6
TIL from one patient were divided among three G-Rex100 flasks, A, B
and C. After 7 days in culture the TIL in each flask were split
into 3 equal parts, seeded into 3 G-Rex100 flasks and cultured for
an additional 7 days. The mean number of TIL harvested from each of
the 3 G-Rex100 flasks used for initial expansion was
875.times.10.sup.6.+-.30.8.times.10.sup.6 and ranged from
849.times.10.sup.6 to 909.times.10.sup.6 TIL and the mean number
harvested from each of the 9 G-Rex100 flasks used for the secondary
expansion was 2.63.+-.0.09.times.10.sup.9 and ranged for
2.55.times.10.sup.9 to 2.70.times.10.sup.9 TIL (Table 5).
TABLE-US-00008 TABLE 5 Number of cells produced by a two-step
G-Rex100 TIL rapid expansion protocol (REP); the first step
involved growth in 3 G-Rex100 flasks and the second growth in 9
G-Rex100 flasks First Second G-Rex100 G-Rex100 Flask Day 0 Day 7
Flask Day 11 Day 14 Post Wash A 5 .times. 10.sup.6 849 .times.
10.sup.6 A1 1.44 .times. 10.sup.9 2.67 .times. 10.sup.9 A2 N.T.
2.43 .times. 10.sup.9 A3 N.T. 2.66 .times. 10.sup.9 B 5 .times.
10.sup.6 867 .times. 10.sup.6 B1 1.55 .times. 10.sup.9 2.70 .times.
10.sup.9 B2 N.T. 2.66 .times. 10.sup.9 B3 N.T. 2.76 .times.
10.sup.9 C 5 .times. 10.sup.6 909 .times. 10.sup.6 C1 1.44 .times.
10.sup.9 2.62 .times. 10.sup.9 C2 N.T. 2.60 .times. 10.sup.9 C3
N.T. 2.55 .times. 10.sup.9 Total 15 .times. 10.sup.6 2.63 .times.
10.sup.9 14 .times. 10.sup.9 23.6 .times. 10.sup.9 21.0 .times.
10.sup.9
[0080] The total TIL yield was 23.6.times.10.sup.9 and
21.0.times.10.sup.9 remained after washing the cells. The viability
of the cells was 96% and 69% of the cells expressed CD3 and
CD8.
[0081] Cell potency, in terms of interferon (IFN)-.gamma. secretion
was also tested using Enzyme-linked immunosorbant assay (ELISA).
The cells grown using the gas-permeable G-Rex100 containers and the
cells grown using non-gas permeable containers produced a
comparable amount of IFN-.gamma..
Example 7
[0082] This example demonstrates the rapid expansion of TIL using
one 5000 mL gas permeable container.
[0083] While serial expansion of TIL in G-Rex100 flasks required
far less regents, less incubator space, less labor and less
specialized equipment than REP in T-flasks and gas-permeable bags,
it was hypothesized that the gas-permeable cultureware REP process
could be further improved by using one large vessel rather than 9
G-Rex100 flasks. Therefore, a larger vessel with a gas-permeable
membrane with approximately 6.5 times the gas permeable surface
area and 10 times the volume of the G-Rex100 flasks was tested.
This vessel was the GP5000 (providing about 650 cm.sup.2 of surface
area for growth of the TIL). Two different REP methods using GP5000
gas-permeable vessels were tested. One method involved an initial
7-day expansion in 2 G-Rex100 flasks, each seeded with
5.times.10.sup.6 TIL, followed by another expansion of the
harvested TIL in a single GP5000 vessel. The other method involved
a single 14-day expansion of 10.times.10.sup.6 TIL in a GP5000
vessel.
[0084] Cells from 2 patients were tested and the TIL yield of the
two REP methods were similar for both donors. Approximately
25.times.10.sup.9 TIL were harvested from patient 3524 and
approximately 20.times.10.sup.9 from patient 3560. The cell
viability for all four REPs was >96% and >92% of patient 3524
cells expressed CD8 and >35% of patient 3560 cells expressed
CD8.
Example 8
[0085] This example demonstrates a clinical TIL production
process.
[0086] Clinical scale TIL production using tumor fragments from 3
patients was next tested by initially culturing TIL in G-Rex10
flasks followed by REP in G-Rex100 flasks. For each patient, 6
G-Rex10 flasks were seeded with 5 tumor fragments and after 14 to
15 days 5.times.10.sup.6 TIL from each G-Rex10 flask were seeded
into one G-Rex100 flask. After 7 days TIL from each G-Rex100 flask
were split into 3 G-Rex100 flasks and after an additional 7 days in
culture TIL were harvested from the 18 G-Rex100 flasks. For two
patients, 3613 and 3618, enough TIL could be harvested from each of
the 6 G-Rex10 flasks for TIL REP in a G-Rex100 flask.
[0087] The quantity of TIL harvested from each of the G-Rex10
flasks ranged from 47.5 to 97.8.times.10.sup.6 cells for patient
3613 and 24.6 to 64.2.times.10.sup.6 for patient 3618 (Table 6A).
For patient 3625 sufficient quantities of TIL were obtained from 4
of the 6 G-Rex10 flasks. The quantity harvested from these 4 flasks
ranged from 59.7 to 140.times.10.sup.6 cells (Table 6A). For
patients 3613 and 3618, 5.times.10.sup.6 TIL from each of the 6
G-Rex10 flasks was seeded into a G-Rex100 flask. For patient 3625,
5.times.10.sup.6 TIL from 2 G-Rex10 flasks were each seeded into
one G-Rex100 flask and 10.times.10.sup.6 TIL from the other 2
G-Rex10 flasks were split and used to seed 4 G-Rex100 each with
5.times.10.sup.6 TIL. At the completion of REP using patient 3613
cells 22.4.times.10.sup.9 TIL were harvested, while REP using
patient 3618 cells yielded 52.7.times.10.sup.9 TIL and patient 3625
cells yielded 61.0.times.10.sup.9 TIL. The number of TIL produced
by each of the 6 sets of 3 G-Rex100 flasks was similar for each
patient. These results show that G-Rex100 flasks can produce
sufficient quantities of TIL for clinical therapy using TIL
initially cultured from tumor fragments in G-Rex10 flasks. The same
G-Rex100 REP protocol was also successful in expanding TIL that
were initially cultured from tumor fragments in 24-well plates.
There were no significant differences in fold expansion using
either TIL initially cultured from tumor fragments in 24-well
plates or G-Rex10 flasks.
TABLE-US-00009 TABLE 6A TIL # of Phenotype Patient Culture
Fragments Day TIL # TIL #TIL/ Viability (% CD3+ # Vessel Seeded
Harvested Harvested Fragment (%) CD8+) 3613 1 5 14 47.5 .times.
10.sup.6 9.50 .times. 10.sup.6 N.T. 70 2 5 14 94.5 .times. 10.sup.6
18.9 .times. 10.sup.6 N.T. 74 3 5 14 57.5 .times. 10.sup.6 11.5
.times. 10.sup.6 N.T. 74 4 5 14 97.8 .times. 10.sup.6 19.6 .times.
10.sup.6 N.T. 73 5 5 14 55.0 .times. 10.sup.6 11.0 .times. 10.sup.6
N.T. 67 6 5 14 67.0 .times. 10.sup.6 13.4 .times. 10.sup.6 N.T. 67
3618 1 5 14 61.0 .times. 10.sup.6 12.2 .times. 10.sup.6 99.0 77 2 5
14 64.2 .times. 10.sup.6 12.8 .times. 10.sup.7 97.0 84 3 5 14 24.6
.times. 10.sup.6 4.92 .times. 10.sup.6 99.2 N.T. 4 5 14 64.2
.times. 10.sup.6 12.8 .times. 10.sup.6 96.4 86 5 5 14 40.2 .times.
10.sup.6 8.04 .times. 10.sup.6 97.1 77 6 5 14 57.0 .times. 10.sup.6
11.4 .times. 10.sup.6 99.3 85 3625 1 5 15 86.0 .times. 10.sup.6
17.2 .times. 10.sup.6 96.8 73 2 5 15 59.4 .times. 10.sup.6 11.9
.times. 10.sup.6 98.7 91 3 5 15 71.8 .times. 10.sup.6 14.4 .times.
10.sup.6 98.6 73 4 5 15 1.80 .times. 10.sup.6** 0.36 .times.
10.sup.6 64.3 N.T. 5 5 15 2.20 .times. 10.sup.6** 0.440 .times.
10.sup.6 78.6 N.T. 6 5 15 140 .times. 10.sup.6 28.0 .times.
10.sup.6 100.0 74 N.T. = Not Tested **Insufficient number of cells
for clinical REP
Example 9
[0088] This example demonstrates that expanding TIL in gas
permeable containers uses a lower number of containers, lower
number of feeder cells, and lower amount of medium as compared to
methods in which the TIL are expanded in non-gas permeable
containers.
[0089] TIL are expanded as described above using gas permeable
containers (G-Rex100 and GP5000) and in non-gas permeable
containers (bags and T 175 flask). A comparison of the numbers of
containers and amounts reagents used is set forth in Table 6B.
TABLE-US-00010 TABLE 6B No. of No. of TIL No. of Feeder Volume of
Containers seeded Cells Medium T 175 Flask 20-40 20 .times.
10.sup.6- 4 .times. 10.sup.9-8 .times. ~30,000 ml Flasks 40 .times.
10.sup.6 10.sup.9 (requires 2 different types of REP medium)
LIFECELL 10-20 20 .times. 10.sup.6- 4 .times. 10.sup.9-8 .times.
~30,000 ml flasks (Baxter) Bags 40 .times. 10.sup.6 10.sup.9 500 mL
gas 12-18 20 .times. 10.sup.6- 2 .times. 10.sup.9-2 .times. 5800
ml-8700 permeable 30 .times. 10.sup.6 10.sup.9 ml (only 1 REP
container (G- medium is Rex100) necessary) 5000 mL gas 2 20 .times.
10.sup.6- 2 .times. 10.sup.9-2 .times. 5800 ml-8700 permeable 30
.times. 10.sup.6 10.sup.9 ml (only 1 REP container medium is
(GP5000) necessary)
Example 10
[0090] This example demonstrates that culturing TIL in unfiltered
cell medium has little or no detrimental effects on TIL growth.
[0091] TIL (4.times.10.sup.6) were cultured in filtered or
unfiltered complete medium (CM) (50 mL) (RPMI 1640 with glutamine,
supplemented with 10% AB serum, 25 mM Hepes and 10 .mu.g/ml
gentamicin) in four wells. On day 7/8, fold increase, viability,
and % CD3+CD8+ were measured. The results are shown in Table 7.
TABLE-US-00011 TABLE 7 Fold Increase Viability % CD3+CD8+ Group
#2812 #3289 #2812 #3289 #2812 #3289 Filtered 2.02 9.62 97% 95.2%
59% 90% Medium Unfiltered 2.13 9.40 96.5% 95.9% 60.2% 89%
Medium
[0092] The performance of the TIL cultured in the non-filtered
medium was similar to that of the TIL cultured in the filtered
medium. The results suggest that particulate serum components have
little or no detrimental effects on TIL cell growth.
Example 11
[0093] This example demonstrates that culturing TIL in cell medium
that lacks beta-mercaptoethanol (BME) has little or no detrimental
effects on TIL growth or potency.
[0094] TIL were cultured in complete medium (CM) (50 mL) with or
without BME. After 2-3 weeks, population increase, viability, and %
CD3+CD8+ were measured. The results are shown in Table 8.
.times.10.sup.7
TABLE-US-00012 TABLE 8 TIL# Harvest Viability CD3CD8 # of Cells
Day; (Harvest (Harvest Tumor # Group Seeded D17-29) Ratio Day) Day)
3520 +BME 1.80 .times. 10.sup.7 2.72 .times. 10.sup.7 1.51 93.40%
59.60% -BME 1.80 .times. 10.sup.7 2.11 .times. 10.sup.7 1.17 93.30%
31.60% 3522 +BME 3.00 .times. 10.sup.7 4.18 .times. 10.sup.7 1.39
94.80% 51.40% -BME 3.00 .times. 10.sup.7 4.39 .times. 10.sup.7 1.46
95.10% 48.70% 3523 +BME 3.00 .times. 10.sup.7 6.75 .times. 10.sup.7
2.25 95.50% 33.90% -BME 3.00 .times. 10.sup.7 6.90 .times. 10.sup.7
2.30 93.60% 37.60% 3524 +BME 1.80 .times. 10.sup.7 1.17 .times.
10.sup.8 6.52 94.50% 91.10% -BME 1.80 .times. 10.sup.7 1.12 .times.
10.sup.8 6.23 95.00% 86.50%
[0095] The performance of the TIL cultured in the medium without
BME was similar to that of the TIL cultured in the medium with
BME.
[0096] Potency of the TIL is measured and compared for TIL cultured
in medium with or without BME. Effector (TIL) cells
(1.times.10.sup.5) are co-cultured with target (antigen-presenting
tumor cells) cells (1.times.10.sup.5), with AK1700 used as a
negative control and DM5 A2 used as a positive control. IFN-gamma
secretion is measured by ELISA. There was no significant difference
in IFN-gamma secretion for the TIL cultured in medium without BME
as compared to TIL cultured in medium with BME. Thus, the absence
of BME from the medium has little or no detrimental effects on TIL
cell growth or potency.
Example 12
[0097] This example demonstrates that feeding the TIL no more
frequently than every third or fourth day during expansion of the
number of TIL in a gas permeable container has little or no
detrimental effects on TIL growth.
[0098] TIL were rapidly expanded in a 500 mL gas permeable
container (G-Rex100) as described above and fed as described in
Table 9. At the end of 14 days, fold expansion, viability, and
composition were measured.
TABLE-US-00013 TABLE 9 Day 14 Original Day 7 Day 9 Day 11 Day 13
(total) Standard 100 ml +100 ml +50 ml +100 ml +50 ml 400 ml (Fed
every other day) Modified 100 ml +150 ml -- +150 ml -- 400 ml (Fed
every third or fourth Day
[0099] There was no difference in the fold expansion observed for
TIL fed every third or fourth day as compared to TIL fed every
other day. Viability and cell composition are set forth in Table
10.
TABLE-US-00014 TABLE 10 Viability Phenotyping (%) Sample Group (%)
CD3 CD3CD4 CD3CD8 CD56 #2761 Standard 98.1 98.4 40.4 49.3 0.6
Modified 97.7 98.6 39.9 51.8 0.5 #3522 Standard 98.9 96.8 29.9 59.9
1.6 Modified 98.4 97.0 28.8 60.2 1.5 #3523 Standard 96.1 98.3 20.0
72.3 0.2 Modified 95.7 98.4 20.2 72.1 0.2 #3524 Standard 92.7 99.1
1.5 95.5 0.1 Modified 90.2 99.3 1.4 95.2 0.1
[0100] Potency of the TIL is measured and compared for TIL cultured
and fed every third or fourth day as compared to TIL fed every
other day. Effector cells (1.times.10.sup.5) are co-cultured with
target cells (1.times.10.sup.5), with AK1700 used as a negative
control and DM5 A2 used as a positive control. IFN-gamma secretion
is measured by ELISA. There was no significant difference in
IFN-gamma secretion for the TIL fed every third or fourth day as
compared to TIL fed every other day. Thus, the reduction in feeding
frequency has little or no detrimental effects on TIL potency.
[0101] There was no difference in viability or cell composition
observed for TIL fed every third of fourth day as compared to TIL
fed every other day.
Example 13
[0102] This example demonstrates that using no more than one type
of cell culture medium for expanding the number of TIL has little
or no detrimental effects on TIL growth.
[0103] TIL were rapidly expanded as described above using no more
than one type of cell culture medium or two types of cell culture
medium as set forth in Table 11.
TABLE-US-00015 TABLE 11 Day 0 Day 5 Day 7 Day 11 Standard 50% RPMI
50% RPMI 100% AIM-V 100% (2 medium 50% AIM-V 50% AIM-V 5% Serum +
AIM-V + types) 5% Serum + 5% Serum + GlutaMAX + GlutaMAX + Hepes +
Hepes + IL-2 IL-2 IL-2 + IL-2 OKT3 Modified 100% AIM-V 100% AIM-V
100% AIM-V 100% (No more 5% Serum + 5% Serum + 5% Serum + AIM-V +
than 1 GlutaMAX + GlutaMAX + GlutaMAX + GlutaMAX + medium IL-2 +
IL-2 IL-2 IL-2 type) OKT3
[0104] There was no difference in the fold expansion observed for
TIL expanded using no more than one type of cell culture medium as
compared to TIL expanded using two types of cell culture medium.
Viability and cell composition are set forth in Table 12.
TABLE-US-00016 TABLE 12 Phenotyping NT (not tested) Sample Group
Viability CD3 CD3CD4 CD3CD8 CD56 3524 50/50 96.5% 98.40% 1.80%
94.20% 0.30% AIM-V 97.0% 98.10% 1.70% 92.00% 0.30% 3546 50/50 97.7%
NT NT NT NT AIM-V 96.8% NT NT NT NT 3552 50/50 96.2% 95.60% 21.30%
70.50% 0.20% AIM-V 97.3% 94.80% 24.80% 65.80% 0.20%
[0105] There was no difference in the viability or cell composition
observed for TIL expanded using no more than one type of cell
culture medium as compared to TIL expanded using two types of cell
culture medium.
[0106] Potency of the TIL is measured and compared for TIL expanded
using no more than one type of medium and TIL expanded using two
types of medium. Effector cells (1.times.10.sup.5) are co-cultured
with target cells (1.times.10.sup.5), with AK1700 used as a
negative control and DM5 A2 used as a positive control. IFN-gamma
secretion is measured by ELISA. There was no significant difference
in IFN-gamma secretion for TIL expanded using no more than one type
of cell medium as compared to TIL expanded using two types of cell
medium.
Example 14
[0107] This example demonstrates that expanding the number of TIL
using a higher ratio of feeders provides a higher number of
TIL.
[0108] TIL (5.times.10.sup.6) from two tumor samples were expanded
as described above using allogeneic feeder cells at a TIL:Feeder
cell ratio of 1:100, 1:50, or 1:25. Cells were counted on days 7,
11, and 14. Viability and cellular composition were evaluated on
day 14.
[0109] There was no difference in cell number between the three
groups at Day 7. At Days 11 and 14, however, expansion using a
higher ratio of feeder cells corresponds with a better expansion of
the number of TIL (9.9.times.10.sup.9 TIL at 1:100 ratio;
8.times.10.sup.9 at 1:50 ratio, and 5.8.times.10.sup.9 at a 1:25
ratio at Day 14 for Sample 1 and 1.0.times.10.sup.10 TIL at 1:100
ratio; 1.0.times.10.sup.10 at 1:50 ratio, and 8.0.times.10.sup.9 at
a 1:25 ratio at Day 14 for Sample 2).
Example 15
[0110] This example demonstrates that TIL cultured in a gas
permeable container have the same or better potency as compared to
TIL cultured in non-gas permeable, 24 well plates.
[0111] TIL are cultured in a gas permeable container (40 mL,
G-Rex10) or in a non-gas permeable, 24-well plate. Effector cells
(1.times.10.sup.5) are co-cultured with target cells
(1.times.10.sup.5), with AK1700 used as a negative control and DM5
A2 used as a positive control. IFN-gamma secretion is measured by
ELISA. The results are shown in Table 13.
TABLE-US-00017 TABLE 13 Melanoma Cell Line A2- A2+ Tumor Samples
888 938 526 624 2976-1,2 2998 3524 3552 3560 3561 3556 None A1,24
A1,24 A2,3 A2,3 A3,31 A2 A2,25 A1,2 A2,23 A1,24 A1,66 None 0 0 0 0
0 12 10 0 0 0 0 0 AK1700-3 1 0 0 89 249 85 >2495 177 45 113 1
239 DM5 22 10 11 >1903 >2527 66 >1207 1275 161 118 3 73
3556 24 90 294 93 149 100 525 >1811 409 157 310 NT >1541 well
plate 3556 87 230 88 129 110 308 >1494 340 338 388 NT >1577
G-Rex10 3552 24 114 70 142 >1295 >1763 184 621 627 139 149 NT
212 well plate 3552 81 388 >1699 >2239 >2470 363 >1773
>1452 282 307 NT 256 G-Rex10 3560 24 135 94 110 196 372 173 346
484 175 318 NT >1008 well plate 3560 104 168 141 483 624 240 870
453 212 572 NT >1004 G-Rex10 3561 24 70 539 305 166 327 456 402
205 97 264 207 252 well plate 3561 84 1215 419 113 216 515 323 265
128 329 253 290 G-Rex10
[0112] There was no significant difference in IFN-gamma secretion
for TIL cultured in gas permeable containers as compared to TIL
cultured in non-gas permeable 24 well plates.
Example 16
[0113] This example demonstrates the treatment of melanoma using
TIL prepared by initially culturing the TIL in gas permeable flasks
and then rapidly expanding the number of TIL in gas permeable
flasks. Tumor tissue samples were obtained from seven melanoma
patients. The tumor tissue samples were cultured in G-Rex10 flasks.
TIL were obtained from the cultured tumor tissue samples. The
numbers of TIL were expanded in G-Rex100 flasks. The expanded cells
were administered to the patients.
[0114] Seven patients were treated. One patient (1) had an
objective response (OR) by Response Evaluation Criteria In Solid
Tumors (RECIST) standards. Six patients (6) were non-responders
(NR).
Example 17
[0115] This example demonstrates the treatment of melanoma using
TIL prepared by expanding the number of selected TIL in gas
permeable flasks.
[0116] Tumor tissue samples were obtained from 55 melanoma
patients. Compete medium (2 ml) (supplemented with 6000 IU/ml IL-2)
was added to the wells in the top row of each 24-well plate. A
single fragment of tumor was added to each media-containing
well.
[0117] TIL were obtained from the tumor tissue samples and cultured
as follows. Fragments were incubated in multiwell plates in a
humidified incubator at 37.degree. C., with 5% CO.sub.2 in air for
5 days without disturbance. After 5 days, the TIL cultures in
plates were monitored for growth by viewing with an inverted light
microscope. At this point TIL and other cell types have
extravasated from the fragment and/or propagated in the wells. Half
of the CM in plates was replaced with fresh CM containing IL-2
(6000 IU/ml). Media (1 ml) was aspirated, taking care not to
disturb the cells on the bottom of the well, and replaced with 1 ml
of fresh medium containing IL-2 (6000 CU/ml). Every 2-3 days, or
approximately 3 times per week, the plates were monitored for TIL
growth. When TIL expansion was evident, a sample from the well was
counted to quantify cell concentration. When the culture exceeded
1.times.10.sup.6 lymphocytes/ml or became nearly confluent then the
well was split 1:2. Splitting was accomplished by mixing gently
with a transfer pipette and transferring 1 ml of culture to a new
well, then adding 1 ml of CM containing IL-2 (6000 IU/ml) to each
daughter well. Fragment cultures that showed growth, up to 24 in
total, were split in to 2 wells. The first 12 fragment cultures
that required a second split in to 4 wells were maintained. The
remaining fragment cultures were frozen as a pool 1 (PF1).
Typically, 8 fragment cultures were carried through to an 8 well
split and maintained for therapy. The remaining cultures were
frozen as pool 2 (PF2). The fragments that were being maintained
for therapy were analyzed by FACS for CD3, CD4, CD8 and CD56
content as close to the date of REP as possible.
[0118] The cultures were screened for specificity by co-culturing
100 .mu.l of TIL with media only, autologous fresh tumor cells, or
autologous fresh tumor cells and MHC Class I antibody, and
IFN-.gamma. release was measured. Reactive cultures were selected
for expansion.
[0119] The numbers of TIL (from the selected cultures that released
200 pg/ml or more of IFN-.gamma.) were expanded in G-Rex100 flasks.
The expanded cells were administered to the patients.
[0120] Out of fifty-five patients treated, 18 experienced tumor
regression of greater than 30% and 24 did not experience tumor
regression of at least 30%. The treatment outcome of the remaining
13 patients has not yet been evaluated.
[0121] All references, including publications, patent applications,
and patents, cited herein are hereby incorporated by reference to
the same extent as if each reference were individually and
specifically indicated to be incorporated by reference and were set
forth in its entirety herein.
[0122] The use of the terms "a" and "an" and "the" and similar
referents in the context of describing the invention (especially in
the context of the following claims) are to be construed to cover
both the singular and the plural, unless otherwise indicated herein
or clearly contradicted by context. The terms "comprising,"
"having," "including," and "containing" are to be construed as
open-ended terms (i.e., meaning "including, but not limited to,")
unless otherwise noted. Recitation of ranges of values herein are
merely intended to serve as a shorthand method of referring
individually to each separate value falling within the range,
unless otherwise indicated herein, and each separate value is
incorporated into the specification as if it were individually
recited herein. All methods described herein can be performed in
any suitable order unless otherwise indicated herein or otherwise
clearly contradicted by context. The use of any and all examples,
or exemplary language (e.g., "such as") provided herein, is
intended merely to better illuminate the invention and does not
pose a limitation on the scope of the invention unless otherwise
claimed. No language in the specification should be construed as
indicating any non-claimed element as essential to the practice of
the invention.
[0123] Preferred embodiments of this invention are described
herein, including the best mode known to the inventors for carrying
out the invention. Variations of those preferred embodiments may
become apparent to those of ordinary skill in the art upon reading
the foregoing description. The inventors expect skilled artisans to
employ such variations as appropriate, and the inventors intend for
the invention to be practiced otherwise than as specifically
described herein. Accordingly, this invention includes all
modifications and equivalents of the subject matter recited in the
claims appended hereto as permitted by applicable law. Moreover,
any combination of the above-described elements in all possible
variations thereof is encompassed by the invention unless otherwise
indicated herein or otherwise clearly contradicted by context.
* * * * *